Direct-to-consumer advertising of COX-2 inhibitors: effect on appropriateness of prescribing.
Med Care Res Rev
; 62(5): 544-59, 2005 Oct.
Article
em En
| MEDLINE
| ID: mdl-16177457
ABSTRACT
Spending on direct-to-consumer advertising (DTCA) of prescription drugs has increased dramatically in the past several years. An unresolved question is whether such advertising leads to inappropriate prescribing. In this study, the authors use survey and administrative data to determine the association of DTCA with the appropriate prescribing of cyclooxygenase-2 (COX-2) inhibitors for 1,382 patients. Treatment with either a COX-2 or a traditional nonsteroidal anti-inflammatory drug (NSAID) was defined as appropriate or not according to three different definitions of gastrointestinal risk. Patients who saw or heard a COX-2 advertisement and asked their physician about the advertised drug were significantly more likely to be prescribed a COX-2 (versus a NSAID, as recommended by evidence-based guidelines) than all other patients. Findings also suggest that some patients may benefit from DTCA. The authors discuss the need for balanced drug information for consumers, increased physician vigilance in prescribing appropriately, and further study of DTCA.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Participação do Paciente
/
Sistemas Pré-Pagos de Saúde
/
Publicidade
/
Indústria Farmacêutica
/
Uso de Medicamentos
/
Inibidores de Ciclo-Oxigenase 2
Tipo de estudo:
Etiology_studies
/
Guideline
/
Prognostic_studies
/
Qualitative_research
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article